Supplement: Therapeutic Cancer Vaccine Roundup
Individualized Cell Therapies Come with a Unique Set of Bioprocess Requirements
Supplement: Circumventing Cancer Cells’ Defenses
Cancer Cells Can Exploit Well-Evolved Moves to Evade Immune Detection
Smelly Camel Urine Finding Could Lead to Novel Therapies for Sleeping Sickness
Sounds of Science Podcast
Supplement: Treating “Solid” Tumors with CAR T Cells
The Road to Developing Effective Cancer Immunotherapies Using CAR T Cells Has Been a Long and Sometimes Rocky One
For full access to this article login to GEN Select now.
Hopes Dashed for Alzheimer's Patients
The Latest Phase III Failure Perpetuates Skepticism about Developing Drugs for AD
- Hopes for a new drug to treat the symptoms of Alzheimer disease (AD) diminished again on March 3 when Pfizer and Medivation reported Phase III results showing that Dimebon failed to meet its co-primary and secondary efficacy endpoints. Pfizer had shelled out $225 million up front and agreed to ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.